Allyson E. Moore
YOU?
Author Swipe
View article: IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy
IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy Open
Cancer cell therapies have primarily focused on engineering autologous αβ T cells with chimeric antigen receptors (CARs), achieving clinical success against hematologic malignancies. However, their effectiveness against solid tumors is lim…
View article: DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload
DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload Open
We describe a series of DAP12-associated receptors that can be used to achieve multi-targeting within a small genetic payload. Empirical evaluation of scaffold/binder combinations is required to define the optimal synthetic receptor config…
View article: Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling
Electrophilic proximity-inducing synthetic adapters enhance universal T cell function by covalently enforcing immune receptor signaling Open
Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Covalent anchoring of these small molecules represents a useful chemical strategy to enforce proximity; how…
View article: 290 IL-15 is required for optimal anti-tumor activity of Vγ9Vδ2 T cells against glioblastoma
290 IL-15 is required for optimal anti-tumor activity of Vγ9Vδ2 T cells against glioblastoma Open
Background Glioblastoma (GBM) is a clinical unmet need that could benefit from targeted immunotherapy, such as adoptive transfer of engineered T cells. Gamma-delta (γδ) T cells are a promising cellular substrate as they naturally possess t…
View article: LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling
LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling Open
Background The genesis of SMAC mimetic drugs is founded on the observation that many cancers amplify IAP proteins to facilitate their survival, and therefore removal of these pathways would re-sensitize the cells towards apoptosis. It has …